Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...
Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
Vertex Pharmaceuticals (NASDAQ ... Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
Vertex Pharma could be close to succeeding in the ... accompanied by a single-arm safety and effectiveness study of the drug in various surgical and non-surgical pain settings.